𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Optimal two-stage genotyping designs for genome-wide association scans

✍ Scribed by Hansong Wang; Duncan C. Thomas; Itsik Pe'er; Daniel O. Stram

Publisher
John Wiley and Sons
Year
2006
Tongue
English
Weight
182 KB
Volume
30
Category
Article
ISSN
0741-0395

No coin nor oath required. For personal study only.

✦ Synopsis

Abstract

The much‐anticipated fixed‐array, genome‐wide SNP genotyping technologies make large‐scale genome‐wide association scans now possible for large numbers of subjects. In this paper we reconsider the problem (Satagopan and Elston [2003] Genet Epidemiol 25:149–157) of optimizing a two‐stage genotyping design to deal with important new issues that are relevant when studies are expanded from candidate gene size to a genome‐wide scale. We investigate how the basic two‐stage genotyping approach, in which all markers are genotyped in an initial group of subjects (stage I) and only the promising markers are genotyped in additional subjects (stage II), can be used to reduce genotyping cost in a genome‐wide case‐control association study even after allowing for much higher per genotype costs using specially designed assays in stage II, compared to the fixed array of SNPs used in stage I. In addition, we consider the problem of using measured SNPs to make (imperfect) prediction of unmeasured SNPs for association tests of all SNPs (measured or unmeasured) genome wide and the utility of expanding genotyping densities in stage II in the regions where significant associations were detected in stage I. Under a set of reasonable but conservative assumptions, we derive optimal two‐stage design configurations (sample sizes and the thresholds of significance in both stages) with these optimal designs depending both on the total number of markers tested and upon the ratios of cost in stage II versus stage I. In addition we show how existing software for power and sample size calculations can be used for the purpose of designing two‐stage studies, for a wide range of assumptions about the number of markers genotyped and the costs of genotyping in each stage of the study. Genet. Epidemiol. 2006. © 2006 Wiley‐Liss, Inc.

📜 SIMILAR VOLUMES

Optimal designs for two-stage genome-wid
Optimal designs for two-stage genome-wide association studies
✍ Andrew D. Skol; Laura J. Scott; Gonçalo R. Abecasis; Michael Boehnke 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 316 KB 👁 2 views

## Abstract Genome‐wide association (GWA) studies require genotyping hundreds of thousands of markers on thousands of subjects, and are expensive at current genotyping costs. To conserve resources, many GWA studies are adopting a staged design in which a proportion of the available samples are geno

Including sampling and phenotyping costs
Including sampling and phenotyping costs into the optimization of two stage designs for genome wide association studies
✍ Hans-Helge Müller; Roman Pahl; Helmut Schäfer 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 239 KB 👁 1 views

## Abstract We propose optimized two‐stage designs for genome‐wide case‐control association studies, using a hypothesis testing paradigm. To save genotyping costs, the complete marker set is genotyped in a sub‐sample only (stage I). On stage II, the most promising markers are then genotyped in the

Genome-wide association scans identify m
Genome-wide association scans identify multiple confirmed susceptibility loci for Crohn's disease: Lessons for study design
✍ Mark Tremelling; Miles Parkes 📂 Article 📅 2007 🏛 John Wiley and Sons 🌐 English ⚖ 97 KB

The last 12 months have seen unprecedented progress in identifying the susceptibility genes that predispose to common disease in general and Crohn's disease in particular. Success has derived from the new technique of genome-wide association scanning in large panels of cases and controls. This has i